Skip to main content

WEB ACCESSIBLE MR DECISION SUPPORT SYSTEM FOR BRAIN TUMOUR DIAGNOSIS AND PROGNOSIS, INCORPORATING IN VIVO AND EX VIVO GENOMIC AND METABOLIMIC DATA

Objective

Diagnosis and treatment of brain tumours is based on clinical symptoms, radiological appearance, and often a histopathological diagnosis of a biopsy. However, treatment response of histological or radiologically similar tumours can vary widely, particularly for childhood tumours. New technologies are available that may improve tumour classification in terms of diagnosis and prognosis, and may allow individually optimised treatments.

Magnetic Resonance Spectroscopy (MRS) is a non-invasive technique for determining tissue biochemicals (the metabolomic profile). MRS can be performed along with clinical MR Imaging but widespread use is hampered by specialised analysis requirements and poor dissemination of the skills needed to interpret the data. The genomic profile of tumours can be determined with DNA microarrays. Early studies have demonstrated differences in gene expression between tumour grades and between tumour types not easily distinguished by morphologic appearance.

We will bring together the expertise required to study the genomic and metabolomic characteristics of brain tumours, with a multi-centre collaboration to acquire statistically significant data, particularly for rare tumour types. Clinical MRS, high-resolution 1H MRS and gene array analysis of biopsies, will be used to investigate how metabolomic and genomic profiles relate to clinically relevant factors such as survival time and treatment response. As well as providing new scientific data on tumour biology, we will develop the technology for this information to be readily and easily used to help radiologists and neurosurgeons in the management and treatment of brain tumour patients. We will build upon expertise obtained with INTERPRET EU project IST-1999-10310, which created a MRS decision support tool (DSS) for tumour diagnosis. A new web-accessible DSS will be developed, incorporating genomic and metabolomic data, and its diagnostic performance validated.

Call for proposal

FP6-2002-LIFESCIHEALTH
See other projects for this call

Coordinator

UNIVERSITAT DE VALENCIA - ESTUDI GENERAL
Address
Avda. Blasco Ibañez, 13
Valencia
Spain

See on map

Participants (18)

BRUKER BIOSPIN SA.
France
Address
34 Rue De L'industrie
Wissembourg Cedex

See on map

DEUTSCHES KREBSFORSCHUNGSZENTRUM
Germany
Address
Im Neuenheimer Feld 280
Heidelberg

See on map

FUNDACIÓN PARA LA LUCHA CONTRA ENFERMEDADES NEUROLÓGICAS DE LA INFANCIA
Argentina
Address
Montañeses 2325
Ciudad Autonoma De Buenos Aires

See on map

HOSPITAL SANT JOAN DE DÉU
Spain
Address
Passeig Sant Joan De Déu, 2
Esplugues De Llobregat (Barcelona)

See on map

HYPERPHAR GROUP SPA
Italy
Address
Via Pascoli 60
Milan

See on map

INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
France
Address
Rue De Tolbiac 101
Paris

See on map

KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
Address
Oude Markt 13
Leuven

See on map

MEDICAL UNIVERSITY LODZ
Poland
Address
Kosciuszki, 4
Lodz

See on map

MICROART, S.L.
Spain
Address
Viladomat, 291
Barcelona

See on map

PHARMA QUALITY EUROPE, S.R.L.
Italy
Address
Via Dei Poggi, 1
Catelfranco Di Sopra (Arezzo)

See on map

SCITO S.A.
France
Address
5 Place Robert Schuman
Grenoble

See on map

SIEMENS AG, MEDICAL SOLUTIONS
Germany
Address
Henkestrasse 127
Erlangen

See on map

ST GEORGE'S HOSPITAL MEDICAL SCHOOL'
United Kingdom
Address
Cranmer Terrace
London

See on map

STICHTING KATHOLIEKE UNIVERSITEIT
Netherlands
Address
Geert Grooteplein 10
Nijmegen

See on map

THE UNIVERSITY OF NOTTINGHAM
United Kingdom
Address
University Park
Nottingham

See on map

UNIVERSIDAD POLITÉCNICA DE VALENCIA
Spain
Address
Camino De Vera S/n
Valencia

See on map

UNIVERSITAT AUTÒNOMA DE BARCELONA
Spain
Address
Campus Universitat Autònoma De Barcelona
Bellaterra (Cerdanyola Des Vallès)

See on map

UNIVERSITY OF BIRMINGHAM
United Kingdom
Address
Edgbaston
Birmingham

See on map